The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.90
Bid: 2.80
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.20 (7.143%)
Open: 2.90
High: 2.90
Low: 2.84
Prev. Close: 2.90
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

10 Jan 2018 15:19

RNS Number : 5221B
Allergy Therapeutics PLC
10 January 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Allergy Therapeutics PLC

LEI: 213800PQ7AHK7KGVOE23

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Placing of Shares

3. Details of person subject to the notification obligationiv

Name

Invesco Ltd.

City and country of registered office (if applicable)

1555 Peachtree Street NE, Suite 1800,

Atlanta, GA 30309 United States

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

09-01-2018

6. Date on which issuer notified (DD/MM/YYYY):

10-01-2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.81%

0

4.81%

594,117,768

Position of previous notification (if

applicable)

5.62%

0

5.62%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

 

GB00B02LCQ05

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

28,618,373

4.81%

SUBTOTAL 8. A

28,618,373

4.81%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Invesco Asset

Management Limited.

4.81%

0

4.81%

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

Invesco (UK) Ltd.

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

Place of completion

Henley-on-Thames

Date of completion

10-01-2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEASFEFFPPEFF
Date   Source Headline
31st Jan 20187:00 amRNSTrading Update
10th Jan 20183:19 pmRNSHoldings in Company
9th Jan 20187:00 amRNSPQ Birch Phase III trial completes recruitment
12th Dec 20177:00 amRNSCo-development agreement with Ergomed plc
7th Dec 20175:08 pmRNSHolding(s) in Company
22nd Nov 201711:36 amRNSResult of AGM
21st Nov 20177:00 amRNSBlock Listing Application
13th Nov 20177:00 amRNSAllergy Therapeutics to Present at Jefferies 2017
7th Nov 201712:59 pmRNSDirector/PDMR Shareholding
7th Nov 201711:54 amRNSDirector/PDMR Shareholding
19th Oct 20174:14 pmRNSPublication of Annual Report and notice of AGM
19th Oct 20177:00 amRNSCommencement of dosing in PQ Grass Phase II Trial
12th Oct 20175:39 pmRNSHolding(s) in Company
12th Oct 20172:55 pmRNSDirector/PDMR Shareholding
10th Oct 20177:15 amRNSHardman Research: Continuing to gain market share
28th Sep 20177:00 amRNSPreliminary Results
18th Sep 20177:00 amRNSApproval for PQ Grass Phase II trial
11th Sep 20177:00 amRNSExpansion of Clinical Development and R&D teams
15th Aug 20177:00 amRNSNotice of Results
18th Jul 20177:00 amRNSTrading Update
6th Jul 20177:00 amRNSPublication of adjuvant studies in journals
27th Jun 20177:00 amRNSInvestor and analyst site visits
19th Jun 20177:00 amRNSSatellite Symposium at EAACI 2017
6th Jun 20177:00 amRNSDirectorate changes
2nd Jun 201712:55 pmRNSHolding(s) in Company
13th Apr 20177:00 amRNSIssue of Equity
5th Apr 20177:15 amRNSHardman Research: Development across portfolio
29th Mar 20177:00 amRNSInterim Results for six months ended 31 Dec 2016
16th Mar 20177:00 amRNSFirst Patient in Pivotal Phase III Birch Study
9th Mar 20177:00 amRNSNotice of Interim Results
14th Feb 20177:00 amRNSHouse Dust Mite Allergy Vaccine Gains CTA Approval
8th Feb 20177:00 amRNSDirectorate Change
1st Feb 20177:00 amRNSPositive Efficacy & Safety Data in Peanut Vaccine
20th Jan 20177:15 amRNSHardman Research: Investment driving market share
19th Jan 20177:00 amRNSTrading Update
30th Dec 20162:31 pmRNSGrant of Awards
24th Nov 20165:23 pmRNSResult of AGM
2nd Nov 20167:00 amRNSEU Patent Office grants patent for MCT
27th Oct 20161:10 pmRNSIssue of equity in respect of exercise of options
24th Oct 20161:35 pmRNSAnnual Report and Accounts
10th Oct 20167:00 amRNSNew data from novel adjuvant system
3rd Oct 201611:28 amRNSIssue of equity in respect of exercise of options
29th Sep 201612:40 pmRNSDirector/PDMR Shareholding
28th Sep 20167:00 amRNSDirector/PDMR Shareholding
26th Sep 201611:59 amRNSDirector/PDMR Shareholding
26th Sep 201610:46 amRNSHardman Research: Performance drives market share
26th Sep 20167:00 amRNSAllergy Therapeutics Preliminary Results
20th Sep 20164:58 pmRNSIssue of equity in respect of exercise of options
5th Sep 20167:00 amRNSNotice of Preliminary Results
13th Jul 20167:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.